EXAM 4 Flashcards

1
Q

Multiple Myeloma is a malignancy of the ______ cells

A

plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MM can be measured in the ______ and _______

A

plasma
urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the genetic factors of MM

A

familial clusters of MM
Multiple genetic mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What 2 conditions precede MM?

A

Monoclonal gammopathy of undetermined significance
Smoldering MM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the malignant plasma cell involved in unregulated production of a monoclonal antibody

A

M-protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MM cells are in the bone marrow and are further expanded by what 4 “receptors/genes”

A

IL-6
VEGF
IGF-1
NF-kB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the symptoms of MM

A

bone pain
fatigue
infection
neurologic symptoms
polyuria
N/V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What labs will you see with MM?

A

elevated M-protein, SCr, B2-microglobulin, C-reactive protein
hypercalcemia
low hemoglobin, albumin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the acronym for MM symptoms?

A

C: hypercalcemia
R: renal insufficiency
A: anemia
B: bone lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

staging and prognosis of MM includes looking at what labs?

A

serum B2-microglobulin
albumin
LDH
high-risk chromosomal abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Initial therapy for MM includes what regimen?

A

dexamethasone
immunomodulatory drugs
proteasome inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the VRd treatment regimen for MM?

A

Bortezomib
Lenalidomide
Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Candidates for HSCT in MM look at what eligibility factors?

A

age
renal function
performance status
comorbidities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MM maintenance therapy consists of what single agent drugs?

A

Lenalidomide
Bortezomib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

High doses of dexamethasone are associated with what risks?

A

higher risk of infection
CNS toxicity
should be used in caution (especially older patients)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the 3 IMiDs for MM?

A

Thalidomide
Lenalidomide
Pomalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the major side effect for IMiDs in MM?

A

VTE
severe birth defects (REMS program)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are the 3 proteasome inhibitors for MM?

A

Bortezomib
Carflizomib
Ixazomib (PO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Proteasome inhibitors inhibit what “receptor/gene”

A

NF-kB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Bortezomib has less neurotoxicity if given by what route?

A

SQ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Carfilzomib has less _____ compared to bortezomib

A

peripheral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Ixazomib has what side effects?

A

infection (herpes zoster)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What monoclonal antibodies target CD38

A

Daratumumab
Isatuximab-irfc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What monoclonal antibody targets SLAMF7?

A

Elotuzmab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what monoclonal antibody targets BCMA and has a REMS program?

A

Belantamab
REMS program for ophthalmic exam prior to each dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What drug is an oral inhibitor of histone deacetylase enzymes and has a side effects of QTc prolongation?

A

Panobinostat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What drug inhibits nuclear export of tumor suppressor proteins and exportin 1

A

Selinexor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the chimeric antigen receptor T-cell therapy drug for relapsed or refractory MM?

A

idecabtagene vicleucel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the VRd dosing regimen?

A

Lenalidomide PO QD x14 days
Bortezomib SQ days 1,4,8,11
Dexamethasone PO days 1,8,15
repeat Q21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are the bone modifying therapies for supportive care in MM?

A

zoledronic acid (dose adjustments for renal impairment)
pamidronate (reduced dose for renal impairment)
Denosumab (targets RANK-L, no dose adjustments)

32
Q

Myelodysplastic syndrome is characteristed by ineffective hematopoiesis with morphologic dysplasia in what cells?

A

hematopoietic cells
peripheral cytopenias

33
Q

myelodysplastic syndrome is progressive _________ failure, a result of _________ hematopoiesis

A

bone marrow
ineffective

34
Q

neutrophils have reduced ________ and ________ activity despite a normal quantity

A

bacterial and fungal

35
Q

Platelets may be normal in quantity but have impaired _________ , _________ , and _________

A

activation, secretion, and aggregation

36
Q

IPSS classification of MDS is what chromosome abnormalities?

A

5q or 20q deletions and chromosome 7 abnormalities

37
Q

What chromosome abnormalities are part of the IPSS-R system?

A

trisonomy 8 or 19, 12p or 11q deletions and double abnormalities

38
Q

myelodysplastic clone is associated with what cellular dysfunctions?

A

excess secretion of cytokines
defective differentiation
genomic instability
reduced response to regulatory cytokines

39
Q

MDS is associated with what IMMUNE dysregulations?

A

impaired immune surveillance
autoimmune reactions
cytopenias related autoimmune T-cell mediated response

40
Q

What are the 4 prognostic factors for MDS?

A

cytogenetic abnormalities
% of bone marrow blasts
age
number of cytopenias

41
Q

What labs will be observed in MDS?

A

anemia
neutropenia
thrombocytopenia
multiple cytopenias

42
Q

what are the clinical symptoms of MDS?

A

fatigue, lethargy, malaise, palpitations, dyspnea on exertion, exercise intolerance

43
Q

What is treatment for lower-risk MDS?

A

immunomodulating agents
Growth factors
immunosuppressive therapy
hypomethylating agents

44
Q

what are the side effects for thalidomide?

A

fluid retention
peripheral neuropathy
thrombosis
constipation

45
Q

When is a patient a candidate for growth factors in MDS?

A

lower-risk MDS and symptomatic anemia who have a serum EPO level of <500

46
Q

What are the growth factor drugs?

A

filgrastim
luspatercept
eltrombopag

47
Q

What are the agents that modulate effector T-cells (immunosuppressive therapies)

A

antithymocyte globulin (ATG)
cyclosporine
corticosteroids

48
Q

what are the hypomethylating agents to treat MDS?

A

azacitidine
decatabine
azacitadine and venetoclax

49
Q

What are treatment options for higher-risk MDS?

A

DNA hypomethylating agents: prolong overall survival
allogeneic HSCT: only curative option
immunomodulating agents
intensive chemotherapy

50
Q

Venetoclax inhibits?

A

B-cell lymphoma (BCL-2)

51
Q

What is the intensive chemotherapy for higher-risk MDS?

A

anthracycline plus cytarabine
bridge therapy to allogeneic HSCT

52
Q

MDS patients are at risk for?

A

anemia
infections

53
Q

colony stimulating factors stimulate _______ production, increasing the circulating ________, _________ the risk of infection

A

WBC
neutrophils
decreasing

54
Q

What are the hematopoietic growth factors?

A

filgrastim
sargramostim

55
Q

patients with MDS can be treated with transfusions of _______ for anemia, but complications of transfusions include _________

A

RBC
iron overload

56
Q

patients with MDS and a ____ deletion generally have _______ prognosis and are ______ likely to respond to __________

A

5q
favorable
highly
lenalidomide

57
Q

patients with MDS can receive intensive chemotherapy as bridge therapy to HCST to ______ tumor burden and ______ disease while suitable donor is found

A

reduce
control

58
Q

What are some factors associated with the development of Non-Hodgkin lymphoma?

A

genetic diseases
environmental agents
infectious agents
congenital and acquired immunodeficiency states

59
Q

a diet high in _______ increases the risk of NHL?

A

meats and dietary fats

60
Q

What infections are associated with the development of NHL?

A

Epstein-Barr
human T-cell lymphotropic virus type 1
H. pylori
Hep C

61
Q

NHL is derived from proliferation of malignant _______ lymphocytes and their precursors

A

B or T
in the US most is B-cell origin

62
Q

Classification of NHL is based on what 3 things?

A

cell of origin (B or T)
clinical features
morphologic features

63
Q

Most patients with NHL present with what symptom?

A

peripheral lymphadenopathy

64
Q

What are the B symptoms for NHL?

A

fever
weight loss
night sweats

65
Q

what is the gold standard for assessment of almost all lymphoma histology types?

66
Q

Stage I Hodgkin Lymphoma involves how many lymph nodes?

67
Q

Stage II Hodgkin Lymphoma involves?

A

2 or more lymph nodes on the SAME side of the diaphragm

68
Q

stage III Hodgkin Lymphoma involves?

A

lymph node regions on BOTH sides of the diaphragm

68
Q

stage IV Hodgkin Lymphoma involves?

A

diffuse or disseminated involvement of one or more extralymphatic organs or tissues with or without lymphnode enlargement

69
Q

What other factors are used in the staging and prognosis or NHL?

A

A - no symptoms
B - fever, night sweats, weight loss
X - bulky disease
E - involvement of extra lymphatic tissue on one side of the diaphragm
S - involvement of the spleen
CS - clinical stage
PS - pathologic stage